Skip to content

Establishment Labs

US · ESTA #2813 by market cap Listed 2018
63.85 -1.44 -2.21%
Live - 5344 symbols - heartbeat 459s ago · 2026-10-08 06:15
Pre-market 63.52 -0.52%
After-hours 63.85 0.00%
Market cap
1.90B
P/B
88.07
EPS
-1.72
Reader sentiment Are you bullish or bearish on ESTA?

Anonymous reader poll. Unscientific, not investment advice.

Valuation each multiple against its own 5-year range

P/B ratio 90.06 Expensive vs history 78th percentile
5-year average 96.24 · #125 of 125 in Medical Devices
P/E ratio -51.41 Cheap vs history 8th percentile
5-year average -25.75 · forward -92.73
P/S ratio 7.92 Cheap vs history 31st percentile
5-year average 9.07 · forward 6.52 · #106 of 136 in Medical Devices

Vs. peers Medical Devices

Company Market cap P/E (TTM) P/B Div yield
Establishment Labs (ESTA) 1.90B -50.28 88.07 0.00%
Abbott Laboratories (ABT) 170.84B 31.95 3.34 2.47%
Medtronic (MDT) 109.38B 21.06 2.18 3.33%
Stryker Corp (SYK) 105.64B 28.54 4.40 1.26%
Boston Scientific (BSX) 60.26B 16.83 2.42 0.00%
Edwards Lifesciences (EW) 49.44B 49.87 4.66 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value48.90 Economic moatNone UncertaintyHigh

Trading 23.4% above Morningstar's fair value estimate.

Fair value

Establishment Labs Holdings Inc is assigned a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 36% premium over our quantitative fair value estimate of $48.90 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.

The company's valuation metrics undermine our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's enterprise value to EBITDA ratio of 181.5 sits in the top 10% compared with peers globally. This suggests that the value of its enterprise value, or the value of its shares and debt, is a high multiple of the generated EBITDA. We believe this is a sign that shares could be overvalued.

The company's lack of profitability is an additional cause for concern. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's enterprise value to free cash flow ratio, a core component of profitability, ranks in the top 1% compared with global peers. This suggests limited cash flow is available for reinvestment or return to shareholders, which further promotes our unfavorable price/fair value ratio.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.

By Quantitative Equity Report

Quote time 2026-10-08 06:15:08 · For reference only, not investment advice and not tailored to your situation.